DexCom, Inc. (NASDAQ:DXCM) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the DexCom Third Quarter 2025 Earnings Release Conference Call. My name is Abby, and I will be your operator for today's call.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 685,433 | $46,122,787 | +10% | 0.9% |
| 2. | Bailard Inc Thomas Bailard | 56,389 | $3,794,416 | -3% | 0.08% |
| 3. | RWC Asset Management Tord Stallvik (Ceo) | 3,250 | $218,693 | +39% | 0.01% |
| 4. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.01 | 25,000 | $1,250,250.00 | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | $496,100.00 | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | $1,085,000.00 | 121,975 | 2013-03-11 | Filing | |
| $10.37 | 1,000 | $10,369.00 | 6,000 | 2012-03-08 | Filing | |
| $10.34 | 1,000 | $10,340.00 | 5,000 | 2012-03-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $80.86 | 667 | $53,933.62 | 22,667 | 2025-09-05 | Filing | |
| $80.00 | 1,466 | $117,280.00 | 105,223 | 2025-09-04 | Filing | |
| $74.17 | 4,824 | $357,796.08 | 118,657 | 2025-09-02 | Filing | |
| $80.29 | 500 | $40,145.00 | 94,102 | 2025-08-15 | Filing | |
| $81.54 | 195 | $15,900.30 | 51,121 | 2025-08-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,882,168 | $1,068,711,084 | 0.79% | |
| 2. | 10,090,374 | $678,981,248 | 0.4% | |
| 3. | 5,608,475 | $377,394,282 | 0.12% | |
| 4. | 2,533,539 | $170,481,840 | 2.43% | |
| 5. | 1,620,404 | $109,036,985 | 0.37% |
News See All
Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating
DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years.
10 Best NASDAQ Growth Stocks to Buy for the Next 5 Years
On October 24, Peter Oppenheimer, Chief Global Equity Strategist at Goldman Sachs, appeared on CNBC to suggest that the tech rally is grounded in fundamentals, not speculation, though rising excitement...
DexCom, Inc. (DXCM): A Bear Case Theory
We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM.
Here’s Why Artisan Mid Cap Fund Exited Dexcom (DXCM)
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
William Blair Maintains Bullish Stance on DexCom (DXCM) Stock
DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now.
14 Best Long Term Growth Stocks to Buy Now
Morningstar highlighted that, as of Sept. 30, 2025, the US equity market was trading at 3% premium over its fair value estimates.
TD Cowen Maintains its Buy Rating and $100 PT for DexCom, Inc. (DXCM)
On September 25, 2025, given that previous technical problems with the company’s G7 continuous glucose monitoring (CGM) technology had been fixed, TD Cowen kept its buy rating and $100 price target ...
13 Best Quality Stocks to Buy Right Now
In addition to capturing secular growth trends in technology, healthcare, and energy, quality stocks frequently show the capacity to withstand macroeconomic unpredictability, such as geopolitical tensions...
Hedge Fund Resource Center Billionaire Hedge Funds
